HIGHTIDE THERAPEUTICS, INC.

Ajouter à une liste

Communiqués HighTide Therapeutics, Inc.

Actions

2511

KYG4568L1023

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:05 24/07/2026			Varia. 5j.	Varia. 1 janv.
2,650 ^HKD	-1,12%		+1,92%	-10,17%

02/07	HighTide Therapeutics et son PDG resilient un contrat de pret suite aux reserves de la Bourse	MT
04/05	HighTide Therapeutics, Inc. annonce des remaniements au sein de son conseil d'administration et de ses comités, effectifs au 4 mai 2026	CI

Communiqués

05/04	Moving Beyond the 'Blockbuster' Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont	AQ
10/12	HighTide Therapeutics Presents Renal Data for HTD1801, Reinforcing Its Potential as a Foundational CKM Therapy	AQ
31/10/25	HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus	AQ
31/10/25	HighTide Therapeutics - HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus	AQ
17/09/25	EASD 2025 \| HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes	AQ
25/10/24	HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024	AQ
11/09/24	EASD 2024 \| HighTide Therapeutics Presents Oral Reports of Phase 2 Studies	AQ
21/06/24	HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study	AQ
21/06/24	HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)	AQ
07/06/24	HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...	EQ
05/06/24	HighTide Therapeutics Presents Analyses of Phase 2a MASH Study	AQ
05/06/24	HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Tous les transcripts sur plus de 9000 sociétés, le jour de leur publication !

Débloquez-les Maintenant !

Débloquez-les Maintenant !